194 related articles for article (PubMed ID: 25758338)
1. Role of formic receptors in soluble urokinase receptor-induced human vascular smooth muscle migration.
Duru EA; Fu Y; Davies MG
J Surg Res; 2015 May; 195(2):396-405. PubMed ID: 25758338
[TBL] [Abstract][Full Text] [Related]
2. Urokinase-induced smooth muscle cell responses require distinct signaling pathways: a role for the epidermal growth factor receptor.
Nicholl SM; Roztocil E; Davies MG
J Vasc Surg; 2005 Apr; 41(4):672-81. PubMed ID: 15874933
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of kringle fragment of urokinase-induced vascular smooth muscle cell migration.
Roztocil E; Nicholl SM; Davies MG
J Surg Res; 2007 Jul; 141(1):83-90. PubMed ID: 17574041
[TBL] [Abstract][Full Text] [Related]
4. Protease-mediated human smooth muscle cell proliferation by urokinase requires epidermal growth factor receptor transactivation by triple membrane signaling.
Duru EA; Fu Y; Davies MG
J Surg Res; 2014 Dec; 192(2):254-62. PubMed ID: 25082749
[TBL] [Abstract][Full Text] [Related]
5. UPA promotes lipid-loaded vascular smooth muscle cell migration through LRP-1.
Lugano R; Peña E; Casani L; Badimon L; Padró T
Cardiovasc Res; 2013 Nov; 100(2):262-71. PubMed ID: 23812296
[TBL] [Abstract][Full Text] [Related]
6. Vitronectin concentrates proteolytic activity on the cell surface and extracellular matrix by trapping soluble urokinase receptor-urokinase complexes.
Chavakis T; Kanse SM; Yutzy B; Lijnen HR; Preissner KT
Blood; 1998 Apr; 91(7):2305-12. PubMed ID: 9516128
[TBL] [Abstract][Full Text] [Related]
7. Cleavage of the urokinase receptor (uPAR) on oral cancer cells: regulation by transforming growth factor - β1 (TGF-β1) and potential effects on migration and invasion.
Magnussen SN; Hadler-Olsen E; Costea DE; Berg E; Jacobsen CC; Mortensen B; Salo T; Martinez-Zubiaurre I; Winberg JO; Uhlin-Hansen L; Svineng G
BMC Cancer; 2017 May; 17(1):350. PubMed ID: 28526008
[TBL] [Abstract][Full Text] [Related]
8. Urokinase-receptor-mediated phenotypic changes in vascular smooth muscle cells require the involvement of membrane rafts.
Kiyan J; Smith G; Haller H; Dumler I
Biochem J; 2009 Oct; 423(3):343-51. PubMed ID: 19691446
[TBL] [Abstract][Full Text] [Related]
9. Release of soluble urokinase receptor from vascular cells.
Chavakis T; Willuweit AK; Lupu F; Preissner KT; Kanse SM
Thromb Haemost; 2001 Aug; 86(2):686-93. PubMed ID: 11522023
[TBL] [Abstract][Full Text] [Related]
10. Aggregated low-density lipoprotein induce impairment of the cytoskeleton dynamics through urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor in human vascular smooth muscle cell.
Lugano R; Peña E; Badimon L; Padró T
J Thromb Haemost; 2012 Oct; 10(10):2158-67. PubMed ID: 22906080
[TBL] [Abstract][Full Text] [Related]
11. Sphingosine-1-phosphate-induced oxygen free radical generation in smooth muscle cell migration requires Galpha12/13 protein-mediated phospholipase C activation.
Roztocil E; Nicholl SM; Davies MG
J Vasc Surg; 2007 Dec; 46(6):1253-1259. PubMed ID: 18155002
[TBL] [Abstract][Full Text] [Related]
12. Urokinase induces basophil chemotaxis through a urokinase receptor epitope that is an endogenous ligand for formyl peptide receptor-like 1 and -like 2.
de Paulis A; Montuori N; Prevete N; Fiorentino I; Rossi FW; Visconte V; Rossi G; Marone G; Ragno P
J Immunol; 2004 Nov; 173(9):5739-48. PubMed ID: 15494526
[TBL] [Abstract][Full Text] [Related]
13. An uncleavable uPAR mutant allows dissection of signaling pathways in uPA-dependent cell migration.
Mazzieri R; D'Alessio S; Kenmoe RK; Ossowski L; Blasi F
Mol Biol Cell; 2006 Jan; 17(1):367-78. PubMed ID: 16267271
[TBL] [Abstract][Full Text] [Related]
14. The tyrosine phosphatase SHP-2 controls urokinase-dependent signaling and functions in human vascular smooth muscle cells.
Kiyan J; Haller H; Dumler I
Exp Cell Res; 2009 Apr; 315(6):1029-39. PubMed ID: 19133257
[TBL] [Abstract][Full Text] [Related]
15. N-3 long-chain polyunsaturated fatty acids inhibit smooth muscle cell migration by modulating urokinase plasminogen activator receptor through MEK/ERK-dependent and -independent mechanisms.
Whyte C; Thies F; Peyrol L; Balcerzak D
J Nutr Biochem; 2012 Nov; 23(11):1378-83. PubMed ID: 22221673
[TBL] [Abstract][Full Text] [Related]
16. Cell migration in response to the amino-terminal fragment of urokinase requires epidermal growth factor receptor activation through an ADAM-mediated mechanism.
Bakken AM; Protack CD; Roztocil E; Nicholl SM; Davies MG
J Vasc Surg; 2009 May; 49(5):1296-303. PubMed ID: 19394555
[TBL] [Abstract][Full Text] [Related]
17. Monocyte-expressed urokinase regulates human vascular smooth muscle cell migration in a coculture model.
Kusch A; Tkachuk S; Lutter S; Haller H; Dietz R; Lipp M; Dumler I
Biol Chem; 2002 Jan; 383(1):217-21. PubMed ID: 11928816
[TBL] [Abstract][Full Text] [Related]
18. Plasminogen activator inhibitor type-1 gene expression and induced migration in TGF-beta1-stimulated smooth muscle cells is pp60(c-src)/MEK-dependent.
Samarakoon R; Higgins CE; Higgins SP; Kutz SM; Higgins PJ
J Cell Physiol; 2005 Jul; 204(1):236-46. PubMed ID: 15622520
[TBL] [Abstract][Full Text] [Related]
19. suPAR, a soluble form of urokinase plasminogen activator receptor, inhibits human prostate cancer cell growth and invasion.
Piccolella M; Festuccia C; Millimaggi D; Locatelli A; Bologna M; Motta M; Dondi D
Int J Oncol; 2008 Jan; 32(1):185-91. PubMed ID: 18097558
[TBL] [Abstract][Full Text] [Related]
20. Cross-talk between fMLP and vitronectin receptors triggered by urokinase receptor-derived SRSRY peptide.
Gargiulo L; Longanesi-Cattani I; Bifulco K; Franco P; Raiola R; Campiglia P; Grieco P; Peluso G; Stoppelli MP; Carriero MV
J Biol Chem; 2005 Jul; 280(26):25225-32. PubMed ID: 15866865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
